845302-03-6 Usage
Benzene derivative
Contains a benzene ring
A benzene derivative is a compound that has a benzene ring as part of its structure.
Halogenated compound
Contains a bromine atom
A halogenated compound is a molecule in which one or more hydrogen atoms have been replaced by a halogen, in this case, bromine.
Methoxy groups
Contains multiple methoxy groups
Application
Organic synthesis, pharmaceutical research, specialty chemicals, and fine chemicals production
The compound is used as a building block or intermediate in the synthesis of various organic compounds and pharmaceuticals.
Hazardous nature
Requires careful handling
Due to its potential hazards, it is important to handle this chemical with care to avoid accidents or adverse effects.
Reactivity
Valuable building block for synthesis
The compound's properties and reactivity make it a useful starting material for the synthesis of other organic compounds and pharmaceuticals.
Check Digit Verification of cas no
The CAS Registry Mumber 845302-03-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,5,3,0 and 2 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 845302-03:
(8*8)+(7*4)+(6*5)+(5*3)+(4*0)+(3*2)+(2*0)+(1*3)=146
146 % 10 = 6
So 845302-03-6 is a valid CAS Registry Number.
845302-03-6Relevant articles and documents
Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties
Li, Xianfeng,Zhang, Suoming,Zhang, Yong-Kang,Liu, Yang,Ding, Charles Z.,Zhou, Yasheen,Plattner, Jacob J.,Baker, Stephen J.,Bu, Wei,Liu, Liang,Kazmierski, Wieslaw M.,Duan, Maosheng,Grimes, Richard M.,Wright, Lois L.,Smith, Gary K.,Jarvest, Richard L.,Ji, Jing-Jing,Cooper, Joel P.,Tallant, Matthew D.,Crosby, Renae M.,Creech, Katrina,Ni, Zhi-Jie,Zou, Wuxin,Wright, Jon
supporting information; experimental part, p. 2048 - 2054 (2011/04/24)
We have synthesized and evaluated a new series of acyclic P4-benzoxaborole-based HCV NS3 protease inhibitors. Structure-activity relationships were investigated, leading to the identification of compounds 5g and 17 with low nanomolar potency in the enzymatic and cell-based replicon assay. The linker-truncated compound 5j was found to exhibit improved absorption and oral bioavailability in rats, suggesting that further reduction of molecular weight and polar surface area could result in improved drug-like properties of this novel series.
